Trump proposes up to 200% tariffs on imported generic medicines

According to CNBC, President Donald Trump said Tuesday that imported generic medicines would face no tariffs for two years, then a 100% duty for one year before rising to 200%, as his administration weighs measures aimed at boosting U.S. drug manufacturing. The proposal targets a global generic drug industry worth nearly $500 billion and has raised questions about whether producers can shift production to the United States in time. John Murphy III, president and CEO of the Association for Accessible Medicines, said the industry wants policies that support and stabilize access to affordable medicines, while arguing that reimbursement and purchasing pressures continue to discourage more domestic manufacturing. Analysts at Jefferies and Citi said companies with sizable U.S. production, including Amphastar Pharmaceuticals, ANI Pharmaceuticals, Hikma and Fresenius Kabi, appear better positioned, while Teva, Viatris and Apotex have greater exposure because more of their U.S.-sold products are made overseas.